Thread by @haematognomist

🩸Roundup of Myeloid Malignancies/BMT papers, starting w/ something I care a lot about:

1/ Poor Survival & Differential Impact of Genetic Features of Black Patients w/ #AML #leusm

Bhatnagar et al, Cancer Discovery
pubmed.ncbi.nlm.nih.gov/33277314/

We got work to do ya'll 😰 ✊🏾

2/ pubmed.ncbi.nlm.nih.gov/33664234/

Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation

Joshi et. al, Blood Cancer Journal

3/
Post-Transplant Cyclophosphamide (PTCy) is Associated with Increased Cytomegalovirus Infection: A CIBMTR Analysis

Goldsmith et al, Blood
pubmed.ncbi.nlm.nih.gov/33657221/

4/ Midostaurin reduces relapse in FLT3-mutant AML: the Alliance CALGB 10603/RATIFY trial

Larson et al Leukemia
pubmed.ncbi.nlm.nih.gov/33654204/

"Analyses were inconclusive in quantifying the impact of the maintenance phase on the overall outcome. In summary, midostaurin reduces the CIR"

5/ The prognosis and durable clearance of RAS mutations in patients with acute myeloid leukemia receiving induction chemotherapy

Ball et al, American Journal of Hematology
pubmed.ncbi.nlm.nih.gov/33650111/

6/ Identification of leukemic and pre-leukemic stem cells by clonal tracking from single-cell transcriptomics

Velten et al, Nature Communications
pubmed.ncbi.nlm.nih.gov/33649320/

7/ A Ph3 trial of azacitidine vs. a semi-intensive fludarabine & cytarabine schedule in older pts w/ untreated AML

Vives et al, Cancer
pubmed.ncbi.nlm.nih.gov/33626197/

FLUGA = more remissions after 3 cycles, but 1y OS superior w/ AZA...long-term outcomes disappointing: 3y OS, 10% vs 5%)

8/ MRD is complicated fam

pubmed.ncbi.nlm.nih.gov/33618432/

"Post-remission CH in the setting of NPM1mut clearance is common and may result in immunophenotypic changes in myeloid progenitors. It is important to not misinterpret these cells as AML measurable residual disease (MRD)."

9/ "Maintenance with lenalidomide showed no apparent effect on relapse probability in 88 patients randomly assigned for this part of the study."

Löwenberg et al, Blood Adv
pubmed.ncbi.nlm.nih.gov/33616652/